Meta-analysis Comparing Long-Term Clinical Outcomes of Percutaneous Coronary Intervention Versus No Intervention in Patients with Chronic Total Occlusion
Overview
Affiliations
Methods: We performed a meta-analysis to evaluate the efficacy of CTO PCI. The study outcomes were the occurrence of all-cause mortality, myocardial infarction, repeat revascularization, stroke, or freedom from angina at the longest documented follow-up period.
Results: In five trials including 1790 patients, the mean age was 63 ± 10 years, 17% were female, with a median follow-up of 2.9 years. The procedural success rate ranged from 73% to 97% and the right coronary artery was the most involved artery (52%). There was no significant difference between CTO PCI and no intervention regarding all-cause mortality (odds ratio [OR]: 1.10, 95% confidence interval [CI]: 0.49-2.47, = 0.82), myocardial infarction (OR: 1.20, 95% CI: 0.81-1.77, = 0.36), repeat revascularization (OR: 0.67, 95% CI: 0.40-1.14, = 0.14), or stroke (OR: 0.60, 95% CI: 0.26-1.36, = 0.22). In two trials including 686 patients, significantly more patients were free of angina at 1 year, defined as the Canadian Cardiovascular Society grading of angina pectoris Grade 0, in the CTO PCI group compared to the no intervention group (OR: 0.52, 95% CI: 0.35-0.76, < 0.001). Meta-regression analyses based on various trial-level covariates (gender, diabetes, previous myocardial infarction, PCI or coronary artery bypass graft, SYNTAX or J-CTO scores, and CTO-related artery percentages) did not suggest any statistically significant relationships.
Conclusions: CTO PCI appears to have a similar efficacy profile compared to no intervention at long-term follow-up, but with a significant improvement of angina favoring PCI-treated patients. Further adequately powered and long-term trials are required to identify the best management strategy for patients with coronary CTO.
Almendarez M, Alperi A, Pascual I, Alvarez-Velasco R, Lorca R, Hernandez-Vaquero D J Clin Med. 2025; 14(3).
PMID: 39941431 PMC: 11818758. DOI: 10.3390/jcm14030758.
Sigan H, Min L, Zengwei C, Shiyi G, Pinfang K, Dasheng G Atheroscler Plus. 2024; 55:63-73.
PMID: 38414557 PMC: 10897845. DOI: 10.1016/j.athplu.2024.02.001.